Johnson & Johnson Q2 Profit Rises 5.8% Beats Estimates U.S., Global Sales

Johnson & Johnson reported strong second-quarter 2025 earnings, beating analysts' estimates with adjusted earnings per share of $2.77 and sales rising 5.8% to $23.74 billion. The company raised its full-year sales forecast to between $93.2 billion and $93.6 billion, up from the previous range of $91 billion to $91.8 billion, and increased its adjusted EPS guidance to $10.80–$10.90. Robust demand for its cancer drug Darzalex, which generated $3.54 billion in quarterly sales, and strength in its medical device segment were key drivers of growth. The firm also reduced its tariff cost estimate to $200 million for 2025, reflecting a pause on U.S. tariffs on China, though uncertainty remains for 2026. Johnson & Johnson plans to capitalize on a strong product pipeline with anticipated approvals in areas such as lung and bladder cancer, cardiovascular, and mental health. Market analysts generally rate Johnson & Johnson as an outperform stock, with price targets suggesting notable upside from current levels.